shutterstock_1569359980_sundry_photography
Sundry Photography / Shutterstock.com
2 April 2020BiotechSarah Morgan

Gilead fails to overturn $752m BMS patent verdict

A court has rejected  Gilead’s attempt to overturn a $752 million verdict in a patent dispute with  BMS’ Juno Therapeutics over CAR-T therapies.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Biotech
29 September 2026   The gene-editing company has accused a former employee of secretly co-founding a Chinese biotech while still at the company, in a trade secrets lawsuit involving rival base-editing therapies and disputed patent filings.
Biotech
21 September 2026   Judges agreed with the Oxford University spin-out that MGI Tech was likely to infringe Oxford’s patent, and banned sales of certain Cyclone devices to preserve the one-player-market status quo.
Biotech
16 September 2026   BMS is stepping up its defence of its blockbuster cancer drug Opdivo as Amgen moves closer to the biosimilar market.